Does cancer cause autoimmune disease or is it the other way around? In looking at the question of which comes first, the chicken or the egg, researchers at the Garvan Institute of Medical Research in Australia found that a genetic mutation that alters immune cells in leukemia is behind certain autoimmune disorders. Read More
Context Therapeutics Inc. has selected CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to target Claudin-6 (CLDN6)-positive cancers. Resulting from a research collaboration and licensing agreement with Integral Molecular Inc., CTIM-76 is a CLDN6 x CD3 bispecific antibody that incorporates a highly selective CLDN6 binding arm and a CD3 binding single-chain Fv domain in an IgG format with a silenced Fc that is designed to be functionally monovalent to avoid aberrant T-cell activation and to enhance the safety profile. Read More
Endophilin A2 (EndoA2) is a member of the endophilin A family, and is involved in the regulation of neurological and cardiovascular diseases, as well as tumor formation. Researchers from the Second Affiliated Hospital of Guangzhou Medical University assessed the role of EndoA2 in renal fibrosis. Read More
Biondvax Pharmaceuticals Ltd. has reported statistically significant efficacy results from an in vivo proof-of-concept study of its innovative inhaled nanosized antibody (NanoAb) COVID-19 therapy. Read More
Point Biopharma Global Inc. has released new preclinical data from its pan-cancer fibroblast activation protein-α (FAP-α) targeted program, PNT-2004. The preclinical study focused on assessing the potential of the lead candidate in the PNT-2004 clinical program, [177Lu]PNT-6555, in combination with anti-programmed cell death protein 1 (PD-1) immunotherapy. Read More
Sana Biotechnology Inc. has outlined the status of its pipeline following a portfolio prioritization. The company remains on track to file an IND this year for SC-291, the company's HIP-modified, CD19-targeted allogeneic chimeric antigen receptor (CAR) T therapy, with initial clinical data expected next year. Read More
The FDA has awarded orphan drug designation to Sensorion SA's OTOF-GT, a dual vector AAV gene therapy, for the treatment of otoferlin gene-mediated hearing loss. Read More
Carmot Therapeutics Inc. has divulged benzimidazoyl compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of metabolic diseases. Read More
Sotio Biotech AS has exercised its first of five exclusive, target-specific options with Legochem Biosciences Inc. for antibody-drug conjugate (ADC) SOT-106, which is currently being evaluated in preclinical studies in multiple solid tumor indications. Read More
Researchers from Eydis Bio Inc. reported the discovery and preclinical characterization of a novel mitogen-activated protein kinase kinase kinase 7 (MAP3K7/TAK1) inhibitor, EYD-001, being developed for the treatment of inflammatory and neuropathic pain. Read More
Merck Sharp & Dohme Corp. has described 3-oxopiperazine carboxamide derivatives acting as sodium channel protein type 10 subunit alpha (Nav1.8) blockers reported to be useful for the treatment of cough, pruritus, acute and neuropathic pain. Read More
Alzheimer’s disease (AD) is still the most prevalent neurodegenerative disorder, with few FDA-approved treatments and many that have failed; further understanding of AD’s disease mechanisms is required. Investigators from Gempharmatech Inc. have developed a novel AD murine model (FAD4T) in which APP (Swedish and Indiana mutations) and PSEN1 M146L/L286V mutations were inserted into the mice’s genome. Read More
CSPC Pharmaceutical Group Ltd. has received IND approval from the FDA for a phase I study in the U.S. of its antibody-drug conjugate CPO-204 in patients with locally advanced or metastatic urothelial cancer. Read More
Texas A&M University System has discovered 3C-like proteinase (3CLpro) (SARS-CoV-2; COVID-19 virus) and cytochrome P450 3A4 (CYP3A4) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection. Read More
Constellation Pharmaceuticals Inc. has presented three-prime repair exonuclease (TREX) inhibitors reported to be useful for the treatment of cancer. Read More
Eikonoklastes Therapeutics Inc. and Forge Biologics Inc. have established a manufacturing partnership to advance Eikonoklastes' adeno-associated viral (AAV)-based gene therapy, ET-101, into clinical trials for the treatment of patients with amyotrophic lateral sclerosis (ALS). Read More
